Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pocenbrodib

PreclinicalSmall molecule

PPathos AI, Inc.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

MCRPC (metastatic Castration-Resistant Prostate Cancer)Recruiting

MCRPC (metastatic Castration-Resistant Prostate Cancer)Preclinical

Recruiting

Timeline

Expected Milestones

Q2 2029

PreclinicalRecruiting

MCRPC (metastatic Castration-Resistant Prostate Cancer)

NCT06785636

Clinical

Trials by Indication[1]

MCRPC (metastatic Castration-resistant Prostate Cancer)1 trial

PATHWAY: A Phase 1b/2a, Multicenter, Open- Label Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Recruiting·PPathos AI, Inc.·Preclinical·NCT06785636·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pocenbrodib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pocenbrodib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pocenbrodib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pathos AI, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: PPathos AI, Inc.

Related News